Cyanidin-3-O-glucoside attenuates high glucose-induced podocyte dysfunction by inhibiting apoptosis and promoting autophagy via activation of SIRT1/AMPK pathway

Can J Physiol Pharmacol. 2021 Jun;99(6):589-598. doi: 10.1139/cjpp-2020-0341. Epub 2020 Oct 13.

Abstract

Diabetic nephropathy (DN) is a common and complicated chronic kidney disease around the world. To elucidate and find effective therapies of DN is of vital importance. In this paper, we have discovered that cyanidin-3-O-glucoside (C3G), which is one of the anthocyanins, could alleviate high glucose-induced podocyte dysfunction. MTT, flow cytometry assay, and Western blot analysis showed that C3G could reverse the increase of cell apoptosis under high glucose treatment in MPC5 cells by upregulation of Bcl2 and downregulation of Bax and cleaved caspase-3. Moreover, C3G improved the autophagy decrease that was induced by high glucose through regulating the expression level of LC3-II/LC3-I, Beclin1, and p62. In addition, C3G inhibited epithelial-mesenchymal transition (EMT) by increasing E-cadherin and reducing Vimentin. By further study of the mechanisms, we found C3G activated the SIRT1 and AMPK which were inhibited in high glucose condition. Silencing SIRT1 blocked the effect of C3G on regulating cell apoptosis, autophagy, and EMT. In summary, our current findings suggest the protective effect of C3G against high glucose-induced podocyte dysfunction is by improving autophagy and reducing apoptosis and EMT via activating SIRT1/AMPK pathway. It might be a new insight for the treatment of DN.

Keywords: SIRT1/AMPK pathway; apoptose; apoptosis; autophagie; autophagy; axe SIRT1/AMPK; cyanidin-3-O-glucoside; cyanidine-3-O-glucoside; diabetic nephropathy; epithelial-mesenchymal transition; néphropathie diabétique; transition de l’épithélium vers le mésenchyme.

MeSH terms

  • AMP-Activated Protein Kinases* / metabolism
  • Animals
  • Anthocyanins* / pharmacology
  • Apoptosis* / drug effects
  • Autophagy* / drug effects
  • Cell Line
  • Diabetic Nephropathies / drug therapy
  • Diabetic Nephropathies / metabolism
  • Diabetic Nephropathies / pathology
  • Epithelial-Mesenchymal Transition* / drug effects
  • Glucose* / toxicity
  • Glucosides* / pharmacology
  • Mice
  • Podocytes* / drug effects
  • Podocytes* / metabolism
  • Podocytes* / pathology
  • Signal Transduction* / drug effects
  • Sirtuin 1* / metabolism

Substances

  • Anthocyanins
  • cyanidin-3-O-beta-glucopyranoside
  • Sirtuin 1
  • Glucose
  • AMP-Activated Protein Kinases
  • Glucosides